Antisense Oligonucleotide Modulation of SMN2 Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) are inadequate in effectively increasing the inclusion of exon 7 in SMN2 mRNA, leading to insufficient production of functional SMN protein, which is critical for addressing the disease's molecular basis.
Innovation Solution
Administration of an antisense compound complementary to intron 7 of the SMN2 pre-mRNA into the cerebrospinal fluid, specifically through intrathecal injection or infusion, to enhance the inclusion of exon 7 in SMN2 mRNA and subsequent polypeptide, thereby increasing the levels of functional SMN protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to address SMA, then some therapeutic effect is achieved, but the inclusion of exon 7 in SMN2 mRNA is insufficient leading to inadequate production of functional SMN protein
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of oligonucleotides through phosphorothioate internucleoside linkages and 2'-methoxyethyl sugar modifications. These structural parameter changes enhance the oligonucleotide's ability to bind to intron 7 of SMN2 pre-mRNA, thereby increasing exon 7 inclusion levels and improving therapeutic effectiveness.
Solution Approach 2:
The patent uses antisense oligonucleotides as intermediary molecules that mediate between the SMN2 pre-mRNA and the splicing machinery. These oligonucleotides bind to intron 7 and recruit splicing factors to promote exon 7 inclusion, effectively acting as a mediator to increase functional SMN protein production.
2Quantity of substance
If antisense compounds are administered systemically, then the compound can reach target tissues, but the delivery efficiency to the central nervous system is insufficient
Solution Approach 1:
The patent transitions from systemic administration (peripheral route) to direct central nervous system administration (intrathecal or intracerebroventricular route). This dimensional change in administration pathway enables the oligonucleotide to directly reach the spinal cord and brain where SMA pathology occurs, dramatically improving delivery efficiency and reducing the dose required for therapeutic effect.
3Measurement precision
If the oligonucleotide sequence is extended to improve binding affinity, then target recognition increases, but the stability against nucleolytic degradation decreases
Solution Approach 1:
The patent creates a composite oligonucleotide structure combining phosphorothioate internucleoside linkages with 2'-methoxyethyl sugar modifications. This composite chemical structure provides both high binding affinity for intron 7 and enhanced resistance to nucleolytic degradation, resolving the contradiction between sequence length and stability.
Solution Approach 2:
The patent modifies the chemical parameters of the oligonucleotide backbone and sugar moieties. The phosphorothioate linkages and 2'-methoxyethyl groups change the physical-chemical properties to increase nuclease resistance while maintaining or improving binding affinity through optimized sequence composition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the levels of SMN2 mRNA and polypeptide with exon 7, ameliorating SMA symptoms by improving motor function and potentially delaying or reducing the progression of the disease.
Implementation Method 1
an antisense compound comprising an antisense oligonucleotide complementary to intron 7 of a nucleic acid encoding human SMN2 pre-mRNA
Data Source
AI summary
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.